The private equity firm Mutares has pulled off a €105 million capital raise, but the market is far from impressed. Its shares closed at €23.60 on Friday, hitting a fresh 52-week low and trading below the €24.50 placement price that institutional investors paid for the new stock. Since the start of the year, the share price has dropped roughly 21%, underscoring the disconnect between the company’s fundraising success and its market valuation.
A $450 Million Bet on Thermoplastics
The timing of the capital increase is no coincidence. Mutares is in the midst of its largest-ever acquisition: the engineering thermoplastics business of SABIC, valued at around $450 million. The deal is still winding through regulatory approvals, with closing expected in the second half of 2026. The company has also signaled a flurry of transaction activity for the second quarter, including both exits and further purchases.
Roughly 80% of the net proceeds from the rights offering will be deployed in the US market, where Mutares plans to build new platforms and accelerate its acquisition pipeline. The remaining funds are earmarked for European opportunities and balance sheet strengthening.
The Covenant Conundrum
Yet the balance sheet needs more than just a cash injection. Based on preliminary data, management has warned that a key covenant on its outstanding bond may be breached. The ratio of net debt to equity is under pressure, driven by valuation effects and a sharp increase in lease liabilities over the past year.
The auditor is currently signing off on the full-year results, which show a net profit of around €130 million on group revenue of €6.5 billion. Market participants will be scrutinizing the fine print when the audited annual report is published on April 28 — the same day the new shares from the second tranche of the capital increase become tradable.
Should investors sell immediately? Or is it worth buying Mutares?
A Dual-Purpose Cash Pile
The €105 million gross proceeds from the rights issue serve a dual purpose: funding US expansion and shoring up the balance sheet to address the potential covenant breach. The offering saw a subscription rate of about 96%, with the remaining shares fully placed elsewhere. The order book for the pre-placement was nearly three times oversubscribed, with institutional investors from the US and UK taking the bulk of the allocation.
Once the second tranche is registered in the commercial register, the company’s share capital will rise to roughly €25.6 million. Mutares has also outlined plans to start regularly buying back bond tranches of at least €25 million from the second quarter onward.
Operational Momentum Beneath the Headlines
Away from the balance sheet concerns, the portfolio is showing real operational momentum. Investments in energy, defense, and infrastructure are benefiting from structural growth trends. For the portfolio company Efacec, management expects EBITDA of between €40 million and €50 million this year.
The next key dates are already on the calendar. The quarterly report on May 12 will provide early evidence of how quickly deleveraging is progressing. That will be followed by the annual general meeting on July 3, where shareholders will vote on the dividend for the past financial year.
For now, Mutares is walking a tightrope: deploying fresh capital for growth while managing the debt metrics that have put its bond covenant at risk. The market is watching closely, and the share price — languishing at its lowest point in 12 months — suggests investors are waiting for proof that both objectives can be achieved simultaneously.
Ad
Mutares Stock: Buy or Sell?! New Mutares Analysis from April 25 delivers the answer:
The latest Mutares figures speak for themselves: Urgent action needed for Mutares investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 25.
Mutares: Buy or sell? Read more here...
